Related Experiment Video
Updated: Oct 9, 2025

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Cost-effectiveness analysis of intensive blood pressure control in Korea
Ye Seol Lee1,2, Hae-Young Lee3, Tae Hyun Kim4
1Department of Rehabilitation Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Insights
Intensive blood pressure control is more cost-effective for hypertensive patients over 50, even with higher initial costs. Patient medication adherence significantly impacts cost-effectiveness, highlighting the importance of treatment compliance for preventing cardiovascular disease.
Area of Science:
- Health Economics
- Cardiology
- Public Health
Background:
- Hypertension management is crucial for preventing cardiovascular disease (CVD).
- Cost-effectiveness analysis (CEA) informs optimal treatment strategies for chronic conditions like hypertension.
- Understanding the economic impact of intensive versus standard blood pressure (BP) control is vital for healthcare policy.
Purpose of the Study:
- To conduct a cost-effectiveness analysis of intensive versus standard BP control in Korean hypertensive patients.
- To evaluate the impact of varying medication adherence levels on the cost-effectiveness of intensive BP control.
- To determine if intensive BP control is a cost-effective strategy within Korea's willingness-to-pay threshold.
Main Methods:
- A Markov model was constructed to compare intensive (SBP < 120 mmHg) and standard (SBP < 140 mmHg) BP control.
- Quality-adjusted life years (QALYs) were used as the effectiveness measure, incorporating medical and nonmedical costs.
- Five scenarios with different medication adherence rates were analyzed, alongside sensitivity and tornado analyses.
Main Results:
- Intensive BP control demonstrated lower incremental cost-effectiveness ratios (ICERs) across all adherence scenarios compared to standard care.
- The lowest ICER of $1,373 USD was observed with 100% medication adherence.
- All calculated ICERs fell below Korea's willingness-to-pay (WTP) threshold, indicating cost-effectiveness.
Conclusions:
- Intensive blood pressure control is a more cost-effective strategy for managing hypertension and preventing cardiovascular disease in high-risk patients.
- Optimizing patient medication adherence is critical for maximizing the cost-effectiveness of intensive hypertension treatment.
- The findings support the adoption of intensive BP control strategies within healthcare systems, contingent on adherence support.
Abstract:
This study was a cost-effectiveness analysis of intensive blood pressure (BP) control among hypertensive patients in Korea. We constructed a Markov model comparing intensive versus standard BP control treatment and calculated the incremental cost-effectiveness ratio. The study population consisted of hypertensive patients over 50 years old with systolic blood pressures (SBPs) exceeding 140 mmHg and at high risk of cardiovascular disease. Treatment alternatives included lowering the SBP below 120 mmHg (intensive) and 140 mmHg (standard) for target BP. We assumed five scenarios with different medication adherence. The effectiveness variable was quality-adjusted life years (QALYs), and costs included medical costs related to hypertension (HT), complications, and nonmedical costs. In addition, we performed a sensitivity analysis to confirm the robustness of the results of this study. Scenario 5, with 100% medication adherence, showed the lowest incremental cost-effectiveness ratio (ICER) of $1,373 USD, followed by scenario 1 (first 15 years: 62.5%, 16-30 years: 65.2%, after 30 years: 59.5%), scenario 2 (first five years: 62.5% decrease by 5% every five years), and scenario 3 (first 10 years: 62.5% decrease by 10% every 10 years). The ICERs in all scenarios were lower than the willingness to pay (WTP) threshold of $9,492-$32,907 USD in Korea. Tornado analysis showed that the ICERs were changed greatly according to stroke incidence. Intensive treatment of HT prevents cardiovascular disease (CVD); therefore, intensive treatment is more cost-effective than standard treatment despite the consumption of more health resources. ICERs are considerably changed according to medication adherence, confirming the importance of patient adherence to treatment.
Related Concept Videos
Errors occurring during blood pressure monitoring
Several factors...
Pre-Procedural Guidelines for Assessing Blood Pressure
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension and Regulation of Blood Pressure
Assessment of blood pressure in brachial artery(two-step method)

